Skip to main content
. Author manuscript; available in PMC: 2016 Apr 12.
Published in final edited form as: AIDS. 2008 Nov 30;22(18):2501–2508. doi: 10.1097/QAD.0b013e328318f16c

Figure 2.

Figure 2

Percentage of patients with a 65K and/or 66K silent mutation as a function of the number of NRTIs exposed to during treatment (abacavir, stavudine, didanosine, or tenofovir). Total number of patients for each exposure, including those without K65/66K mutations, are shown below each grouping. ANOVA F-test p = 0.01